Qian Li

Prediction of high‐risk factors for ovarian metastasis in patients with endometrial cancer: A large‐sample retrospective case–control study

AbstractObjectiveTo determine the high‐risk factors of ovarian metastasis of endometrial cancer and their impact on prognosis.MethodsA retrospective case–control study was conducted on a large cohort of patients with endometrial cancer.ResultsA total of 1240 patients with endometrial cancer were eligible for analysis, of whom 120 (9.7%) had ovarian metastasis. The patients with endometrial cancer with ovarian metastasis were more likely to have deep myometrial infiltration, lymph node metastasis, and elevated levels of CA125. The median survival was 39 months in patients with ovarian metastasis and 111 months in those without ovarian metastasis (P < 0.001). According to the stratified analysis, the progression‐free survival (PFS) and overall survival in the low‐risk group and PFS in the high‐risk group of patients with endometrial cancer with ovarian metastasis were significantly shorter than those without ovarian metastasis (P < 0.0001, P = 0.0034, and P < 0.0001, respectively).ConclusionDeep myometrial invasion, lymph node metastasis, and elevated levels of CA125 may be independent high‐risk factors for ovarian metastasis in patients with endometrial cancer. Ovarian metastasis has a greater impact on the prognosis of patients with low‐risk endometrial cancer.

Genetically Engineered Artificial Exosome-Constructed Hydrogel for Ovarian Cancer Therapy

Owing to the insidious onset of ovarian cancer, most patients are in the advanced stage with extensive peritoneal metastasis when they are diagnosed. Treatment of peritoneal metastasis from advanced ovarian cancer remains a significant challenge. Inspired by the massive macrophages in the peritoneal environment, here, we reported an artificial exosome-based peritoneal-localized hydrogel to domesticate peritoneal macrophages as the therapeutic target for realizing potent ovarian cancer therapy, where artificial exosomes derived from genetically sialic-acid-binding Ig-like lectin 10 (Siglec-10)-engineered M